Moderna Rallies Over 6% in Past Week Amid Optimism on Melanoma Vaccine and Upcoming Clinical Data

Moderna (NASDAQ: MRNA) shares gained approximately 6.99% over the week ending September 18, closing at $154.04 — a surge that reflects mounting investor enthusiasm around the company’s oncology pipeline and pending clinical data releases. This performance occurred following a broader move to $182.56 by September 22, indicating continued positive momentum. According to MarketBeat, Moderna closed at $182.56 on September 22, up 5.56% that day, with extended trading showing a mild pullback. (As per verified live price: $182.56, +8.34%, as of September 22.)

Investor interest appears focused on Moderna’s investigational melanoma vaccine, intismeran. News platforms note that the stock’s recent rally reflects optimism ahead of upcoming clinical data. MarketBeat reported that shares have surged roughly 500% year-over-year, with momentum accelerating after encouraging developments in intismeran’s Phase 3 results. However, no specific data release or regulatory milestone within the last week has been officially announced. MarketBeat highlights this sentiment as a primary driver behind the current momentum.

Separately, Moderna reported disappointing interim Phase 3 results for its norovirus vaccine candidate, mRNA‑1403, which failed to meet early statistical success criteria. The company is now planning to enroll an additional cohort to continue the study. This development, announced in its Q2 2026 financial report issued July 31, has not been cited as a factor behind the recent stock rise — instead appearing overshadowed by investor optimism around oncology prospects. Despite this, Moderna is preparing for several potential near‑term milestones, including an anticipated U.S. FDA decision on its seasonal flu vaccine, mFLUSIVA, with a PDUFA date of August 5, and upcoming pivotal readouts in oncology and rare disease programs.

In summary, Moderna’s nearly 7% weekly gain reflects investor expectations that upcoming melanoma vaccine data could validate its post‑COVID growth narrative. While the norovirus setback remains unresolved, optimism on the oncology front and upcoming catalysts appear to be the chief drivers of recent stock strength.

Looking ahead, all eyes remain on Moderna’s pipeline updates — particularly any news around melanoma data — as potential triggers for further stock movement. Investors should continue monitoring official company disclosures for confirmed developments and FDA communications for key regulatory timelines.